Insights
NHS England abolished - what does this mean for pharma?
01 Apr 2025This is not about abolishing the NHS, but a plan to redirect money from bureaucracy to frontline treatments of patients.NICE introduces promising improvements to the routing criteria for highly specialised technologies designed to treat rare diseases
13 May 2025The newly approved routing criteria is hoped to clearly define the circumstances for when highly specialised technologies (HSTs) will be routed to the HST programme which is designed to evaluate technologies for ultra-rare debilitating conditions.
ABPI and UK Government bring forward VPAG pricing review
01 May 2025The UK Government and the Association of the British Pharmaceutical Industry (ABPI) have agreed to accelerate the planned review of the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG).The Association of the British Pharmaceutical Industry (ABPI) has issued a policy proposal aimed at supporting the delivery of the NHS 10-Year Plan.
13 May 2025The plan is built around three core shifts in care: from hospital to community, from analogue to digital, and from treatment to prevention. These shifts reference the government’s ambition to deliver economic growth through improved health outcomes.
AI and copyright - moving closer to a solution?
19 Nov 2024Lawmakers are addressing how to govern the use of copyrighted materials for training AI models. This article examines the situation in the UK and Europe.
What can we expect from the new era of clinical trials in the UK?
23 Jan 2025It is hoped that changes to legislation on clinical trials in the UK will quicken the trial approvals process and foster innovation in trial design without compromising patient safety. The amending legislation has been made and will apply in early 2026.
